Suppr超能文献

在一个多民族发展中国家的背景下,对住院 COVID-19 合并 AKI 患者的研究。

A study of hospitalized COVID-19 patients with AKI in a setting of multiracial developing country.

机构信息

Internal Medicine Department, University Malaya Medical Center, Kuala Lumpur, Malaysia.

Pathology Department, University of Malaya, Kuala Lumpur, Malaysia.

出版信息

BMC Nephrol. 2024 Apr 5;25(1):122. doi: 10.1186/s12882-024-03498-x.

Abstract

BACKGROUND

The commonest indication for hospitalization in COVID-19 patients is hypoxemia or severe respiratory symptoms. However, COVID-19 disease may result in extrapulmonary complications including kidney-related pathology. The reported incidence of renal involvement related to COVID infection varies based on geographical location.

OBJECTIVE

This study aimed to assess the incidence rate of AKI in hospitalized COVID-19 patients and identify risk factors and prognostic predictors.

METHOD

In this retrospective study, we recruited hospitalized COVID-19 patients from January 2021 until June 2021 at the University Malaya Medical Center. The inclusion criteria were hospitalized for ≥ 48 h with confirmed COVID-19 infection and at least 18 years old. Patient demographic and clinical data were collected from electronic medical records. The staging of AKI was based on criteria as per KDIGO guidelines.

RESULTS

One thousand five hundred twenty-nine COVID patients fulfilled the inclusion criteria with a male-to-female ratio of 759 (49.6%) to 770 (50.3%). The median age was 55 (IQR: 36-66). 500 patients (32.7%) had diabetes, 621 (40.6%) had hypertension, and 5.6% (n = 85) had pre-existing chronic kidney disease (CKD). The incidence rate of AKI was 21.1% (n = 323). The percentage of COVID patients in different AKI stages of 1,2 and 3 were 16.3%, 2.1%, and 2.7%, respectively. Fifteen hospitalized patients (0.98%) required renal replacement therapy. 58.8% (n = 190) of AKI group had complete recovery of kidney function. Demographic factors included age (p < 0.001), diabetes (p < 0.001), hypertension (p < 0.012), CKD (p < 0.001), and vaccination status (p = 0.042) were associated with an increased risk of developing AKI. We found that the AKI cohort had statistically significant lower platelet counts and higher ferritin levels than the non-AKI cohort. AKI is a risk predictor of prolonged hospitalization (p < 0.001) and higher mortality rates (P < 0.001).

CONCLUSION

AKI is a common clinical complication among hospitalized COVID-19 patients. The etiology of AKI is multifactorial and may have an adverse impact on patient morbidity and mortality.

摘要

背景

COVID-19 患者住院的最常见指征是低氧血症或严重的呼吸道症状。然而,COVID-19 疾病可能导致肺外并发症,包括与肾脏相关的病理。与 COVID 感染相关的肾脏受累的报告发病率因地理位置而异。

目的

本研究旨在评估住院 COVID-19 患者中急性肾损伤 (AKI) 的发生率,并确定风险因素和预后预测因素。

方法

在这项回顾性研究中,我们招募了 2021 年 1 月至 2021 年 6 月期间在马来亚大学医学中心住院的 COVID-19 患者。纳入标准为住院时间≥48 小时,确诊 COVID-19 感染,年龄≥18 岁。从电子病历中收集患者的人口统计学和临床数据。AKI 的分期根据 KDIGO 指南的标准进行。

结果

1529 名 COVID 患者符合纳入标准,男女比例为 759(49.6%)对 770(50.3%)。中位年龄为 55(IQR:36-66)岁。500 名患者(32.7%)患有糖尿病,621 名患者(40.6%)患有高血压,5.6%(n=85)患有慢性肾脏病(CKD)。AKI 的发生率为 21.1%(n=323)。处于不同 AKI 阶段的 COVID 患者比例分别为 1、2 和 3,分别为 16.3%、2.1%和 2.7%。15 名住院患者(0.98%)需要肾脏替代治疗。AKI 组中有 58.8%(n=190)的患者肾功能完全恢复。人口统计学因素包括年龄(p<0.001)、糖尿病(p<0.001)、高血压(p<0.012)、CKD(p<0.001)和疫苗接种状况(p=0.042)与 AKI 风险增加相关。我们发现 AKI 组的血小板计数明显低于非 AKI 组,铁蛋白水平明显高于非 AKI 组。AKI 是延长住院时间(p<0.001)和死亡率升高(P<0.001)的风险预测因素。

结论

AKI 是住院 COVID-19 患者的常见临床并发症。AKI 的病因是多因素的,可能对患者的发病率和死亡率产生不利影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/10998399/1d4b9ac5ecce/12882_2024_3498_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验